Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-risk medulloblastoma: does c-myc amplification overrule histopathology?

Literature DB >> 20063409

High-risk medulloblastoma: does c-myc amplification overrule histopathology?

Eric H Raabe¹, Charles G Eberhart.

Abstract

Entities: Disease Gene Species

Mesh：

Year: 2010 PMID： 20063409 PMCID： PMC4517433 DOI： 10.1002/pbc.22398

Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167

× No keyword cloud information.

14 in total

1. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.

Authors: H G Brown; J L Kepner; E J Perlman; H S Friedman; D R Strother; P K Duffner; L E Kun; P T Goldthwaite; P C Burger
Journal: J Neuropathol Exp Neurol Date: 2000-10 Impact factor: 3.685

2. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors: Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544

3. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.

Authors: Charles G Eberhart; James L Kepner; Patricia T Goldthwaite; Larry E Kun; Patricia K Duffner; Henry S Friedman; Douglas R Strother; Peter C Burger
Journal: Cancer Date: 2002-01-15 Impact factor: 6.860

4. Stratification of medulloblastoma on the basis of histopathological grading.

Authors: Felice Giangaspero; Stefan Wellek; Jun Masuoka; Marco Gessi; Paul Kleihues; Hiroko Ohgaki
Journal: Acta Neuropathol Date: 2006-04-29 Impact factor: 17.088

5. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

Authors: Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson
Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316

6. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.

Authors: M A Grotzer; M D Hogarty; A J Janss; X Liu; H Zhao; A Eggert; L N Sutton; L B Rorke; G M Brodeur; P C Phillips
Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531

7. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.

Authors: Charles G Eberhart; John E Kratz; Amy Schuster; Pat Goldthwaite; Kenneth J Cohen; Elizabeth J Perlman; Peter C Burger
Journal: Brain Pathol Date: 2002-01 Impact factor: 6.508

High-risk medulloblastoma: does c-myc amplification overrule histopathology?

1. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.

2. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

3. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.

4. Stratification of medulloblastoma on the basis of histopathological grading.

5. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

6. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.

7. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.

8. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.

Review 9. Anaplasia and grading in medulloblastomas.

10. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome.

1. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.

Review 2. The clinical implications of medulloblastoma subgroups.